Navan, Biohaven, and The Cooper Shares Plunge on Earnings and Regulatory News

Key Facts

1Navan shares fell 21.7% despite an earnings beat as operating expenses surged 46% and losses widened.

2Biohaven shares dropped 14.9% after the FDA placed a partial clinical hold on its experimental epilepsy drug trials.

3The Cooper Companies shares declined 14.7% following a revenue miss and weaker-than-expected forward guidance.

Amid a volatile trading session, several mid-cap companies faced intense selling pressure driven by disappointing earnings and regulatory hurdles. Navan shares plunged 21.7% despite beating expectations, as a 46% surge in operating expenses caused losses to widen. Biohaven dropped 14.9% following an FDA decision to place a partial clinical hold on its experimental epilepsy drug trials, while The Cooper Companies declined 14.7% after missing revenue estimates and issuing weak forward guidance.

These movements reflect a sharp correction from previous levels, with NAVN priced at $25.89 and BHVN at $15.00 (at close September 9, 2026), per market data. In the healthcare and growth sectors, sentiment was specifically weighed down by the FDA's action against Biohaven, while the revenue miss and soft outlook for The Cooper Companies, whose stock COO closed at $63.48 on September 9, further intensified the downward trend.

Investors should watch for technical support levels following these declines, as BBOT hit a day low of $6.30 and VNCE touched $6.15 (at close September 9, 2026). Looking ahead, the economic calendar shows no immediate catalysts for these specific instruments; however, focus remains on further regulatory updates from the FDA or potential analyst price target revisions.